Aditya Bardia, MD, MPH shares his approach to assessing breast cancer recurrence risk and monitoring patients during and after treatment.
Back
Post-Conference Perspectives: Breast Cancer Recurrence Monitoring by ctDNA
Aditya Bardia, MD, MPH discusses the present and prospective clinical applications of ctDNA monitoring informed by promising data presented at the ASCO 2022 Annual Meeting.
Post-Conference Perspectives: Breast Cancer Recurrence Monitoring by ctDNA
Episodes
All
All
A breast cancer expert provides a brief overview of clinical evidence supporting the use of ctDNA to detect recurrence.
Dr. Bardia reviews data from the ASCO 2022 Annual Meeting, focusing on serial postoperative ctDNA monitoring for breast cancer recurrence.
Clinical pearls addressing the current and potential future applications of ctDNA in breast cancer monitoring strategies.
Experienced clinician shares insight on potential challenges in the use of ctDNA monitoring.
Dr. Bardia discusses promising biomarkers and strategies for helping assess risk and detect recurrence in breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma
4
Trastuzumab Rezetecan Elicits High ORR in HER2-High and HER2-Low Salivary Gland Carcinoma
5